

### Amendments To The Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

#### Listing of Claims:

1. (cancelled)
2. (currently amended) ~~The benzotropolone derivative of claim 1, wherein the derivative is~~ Neotheaflavate B or a salt or an ester of thereof.
3. (currently amended) ~~The benzotropolone derivative of claim 1, wherein the derivative is~~ EGCGCa (Epigallocatechinocatechol gallate) or a salt or an ester of thereof.
4. (currently amended) A composition comprising the neotheaflavate B or a salt or an ester thereof of claim 2 ~~a pharmaceutical or a nutraceutical or a combination thereof, wherein the pharmaceutical or the nutraceutical is effective as an anti-inflammatory agent or antioxidant, wherein the pharmaceutical, the nutraceutical or the combination thereof comprises, as an active ingredient, an effective amount of a benzotropolone derivative as in claim 1.~~
5. (currently amended) ~~The A~~ composition of claim 4, ~~wherein the pharmaceutical or the nutraceutical comprises neotheaflavate B or~~ comprising the EGCGCa or a salt or an ester thereof of claim 3 ~~with the proviso that the benzotropolone derivative is not the neotheaflavate B or EGCGCa.~~
6. (currently amended) The composition of claim 5, further comprising a

pharmaceutically acceptable carrier or diluent, wherein said composition is effective as an anti-inflammatory agent or antioxidant, wherein the pharmaceutical or the nutraceutical comprises the neotheaflavate B or a salt or an ester thereof.

7. (currently amended) The composition of claim 5, wherein the composition is a pharmaceutical or the nutraceutical and is effective as an anti-inflammatory agent or antioxidant ~~comprises the EGCGCa or a salt or an ester thereof.~~

8. (currently amended) The composition of claim 4, wherein the ~~neotheaflavate B or EGCGCa is present in full amount~~ composition is a nutraceutical and is effective as an anti-inflammatory agent or antioxidant.

9. (currently amended) The composition of claim 4, further comprising a pharmaceutically acceptable carrier or diluent, wherein said composition is effective as an ~~An anti-inflammatory agent or antioxidant containing, as the active ingredient, an effective amount of a benzotropolone derivative or a pharmaceutically acceptable salt thereof as claimed in claim 1.~~

10. (currently amended) A method for treating an inflammatory condition comprising administering to a subject in need thereof a composition comprising an amount of ~~a purified benzotropolone derivative~~ (i) neotheaflavate B, a salt or an ester thereof; or (ii) EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof, wherein said amount is effective to treat the inflammatory condition.

11. (currently amended) The method according to claim 10 wherein said amount

~~benzotropolone derivative in the composition administered~~ is at a dosage of between about 0.5 and about 1000 mg per kilogram body weight per day.

12. (currently amended) The method according to claim 10 wherein said amount ~~benzotropolone derivative in the composition administered~~ is at a dosage of between about 1 and about 500 mg per kilogram body weight per day.

13. (currently amended) The method according to claim 10 wherein said composition ~~benzotropolone derivative~~ is administered topically.

14. (currently amended) The method according to claim 10 wherein said composition ~~benzotropolone derivative~~ is administered orally.

15. (currently amended) The method according to claim 10 wherein said composition ~~benzotropolone derivative~~ is administered parenterally.

16. (currently amended) A method of treating or reducing the progression of an inflammatory condition comprising administering to a subject in need thereof a composition comprising an effective amount of (i) neotheaflavate B, a salt or an ester thereof; or (ii) EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof, ~~a benzotropolone derivative~~ and a carrier selected from the group consisting of a pharmaceutically acceptable carrier, veterinary acceptable carrier, dietary supplement carrier and food, ~~wherein said subject is a human or a veterinary animal.~~

17. (original) The method of claim 16, wherein the carrier is a pharmaceutically

acceptable carrier.

18. (original) The method of claim 16, wherein the subject is a human.

19. (original) The method of claim 16, wherein the carrier is a food.

20. (original) The method of claim 16, in which the composition is a dietary supplement.

21. (currently amended) A method for neutralizing free radicals in a patient comprising: administering to the patient in need of such treatment ~~an effective amount of a~~ composition comprising an effective amount of (i) neotheaflavate B, a salt or an ester thereof; or (ii) EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof a ~~pharmaceutical or nutraceutical agent comprising a benzotropolone derivative represented by the general formula;~~

~~wherein R<sub>1</sub> is a hydrogen atom, hydroxyl group, alkoxy group, alkyl group, aryl group, indolyl group, phenyl group, benzyl group, benzopyranyl galloyl group, pyridinyl group, pyrrolyl group, or thiophenyl group;~~

~~wherein R<sub>2</sub> is a hydrogen atom, hydroxyl group, alkoxy group, alkyl group, aryl group, indolyl group, phenyl group, benzyl group, benzopyranyl group, pyridinyl group, pyrrolyl group, or thiophenyl group; and~~

~~wherein R<sub>3</sub> a hydrogen atom, hydroxyl group, alkoxy group, alkyl group, aryl group, indolyl group, phenyl group, benzyl group, pyridinyl group, pyrrolyl group, or thiophenyl group.~~

22. (currently amended) The method of claim 21, wherein the neotheaflavate B or EGCGCa (epigallocatechinocatechol gallate), a salt or an ester thereof ~~benzotropolone derivative~~ is present at a concentration of at least about 0.5%.

23. (currently amended) The method of claim 21, wherein the composition comprises neotheaflavate B, a salt or an ester thereof ~~further comprises a second benzotropolone derivative that is not already selected.~~

24. (currently amended) The method of claim ~~21~~ 23, wherein the composition comprises ~~second benzotropolone derivative is~~ neotheaflavate B or EGCGCa (epigallocatechinocatechol gallate), or a salt or an ester thereof.

25. (currently amended) The method of claim 21, wherein the composition comprises a carrier selected from the group consisting of a pharmaceutically acceptable carrier, veterinary acceptable carrier, dietary supplement carrier and food ~~the pharmaceutical agent.~~

26. (cancelled)

27. (currently amended) A method for synthesizing a benzotropolone derivative ~~by~~ comprising reacting a molecule comprising a pyrogallol unit with a molecule comprising a catechol unit in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

28. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin (EC) and epigallocatechin (EGC) in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

29. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin (EC) and epigallocatechin gallate (EGCG) in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

30. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin gallate(EGC) and epigallocatechin (EGC) in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

31. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin gallate(ECG) and epigallocatechin gallate(EGCG) in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

32. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting catechin (C) and epigallocatechin (EGC) in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

33 (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting catechin (C) and epigallocatechin gallate(EGCG) in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

34. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising treating epicatechin gallate (ECG) with a peroxidase and H<sub>2</sub>O<sub>2</sub>.

35. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin (EC) ~~EC~~ and epicatechin gallate (ECG) ~~ECG~~ in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

36. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting catechin (C) ~~C~~ and epicatechin gallate (ECG) ~~ECG~~ in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

37. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting catechin (C) ~~C~~ and gallic acid in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

38. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin (EC) ~~EC~~ and gallic acid in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

39. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epicatechin gallate (ECG) ~~ECG~~ and gallic acid in the presence of a

peroxidase and H<sub>2</sub>O<sub>2</sub>.

40. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epigallocatechin (EGC) EGC and catechol in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

41. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting epigallocatechin gallate (EGCG) EGCG and catechol in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

42. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting gallic acid and catechol in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

43. (currently amended) The method of claim 27, ~~wherein the reacting molecules are~~ comprising reacting pyrogallol and catechol in the presence of a peroxidase and H<sub>2</sub>O<sub>2</sub>.

44. (currently amended) The method of claim 27, ~~wherein the reacting molecules is~~ comprising treating pyrogallols with a peroxidase and H<sub>2</sub>O<sub>2</sub>.

45. (cancelled)

46. (new) The neotheaflavate B, a salt or an ester thereof of claim 2, which is purified.

47. (new) The EGCGCa (Epigallocatechinocatechol gallate), a salt or an ester thereof of claim 3, which is purified.

48 (new). The method of claim 27, wherein the peroxidase is isolated.